Sanofi's research executives highlighted the start of Phase III studies with the anti-IL-33 Mab itepekimab in chronic obstructive pulmonary disease (COPD), and the expansion of Phase II studies of the selective BTK inhibitor, rilzabrutinib, into atopic dermatitis, asthma and chronic spontaneous urticaria, during the company’s Capital Markets Day on 5 February.
Three years on from the start of retargeting and reorganizing R&D at Sanofi on specialty rather than primary care, Sanofi’s R&D chief John Reed noted the changes had required “enormous trade-offs”, including exiting research areas like cardiovasculars and diabetes, and optimizing the number of research sites, but
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?